• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

    2/14/24 8:20:07 AM ET
    $GRCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRCL alert in real time by email
    SC 13G/A 1 tm246211d1_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    Gracell Biotechnologies Inc.

    (Name of Issuer)

     

    Ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    38406L 103**

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    o Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    ** CUSIP number 38406L 103 has been assigned to the American depositary shares (“ADSs”) of Gracell Biotechnologies Inc. (the “Issuer,”) which are quoted on The Nasdaq Global Select Market under the symbol “GRCL.” Each ADS represents five ordinary shares of the Issuer.  No CUSIP has been assigned to the Issuer’s ordinary shares.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    1 Name of Reporting Person
    William Wei Cao
    2

    Check the Appropriate Box if a Member of a Group

    (a)   ¨

    (b)   ¨  

    3 SEC Use Only 
    4 Citizenship or Place of Organization
    People’s Republic of China 
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    77,141,530(
    1)
    6 Shared Voting Power
    0
    7 Sole Dispositive Power
    77,141,530 (
    1)
    8 Shared Dispositive Power
    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    77,141,530 (
    1) 
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ¨
    11 Percent of Class Represented by Amount in Row 9
    15.9% (
    2)
    12 Type of Reporting Person
    IN
            

     

    (1)Represents (i) 15,049,795 ADSs directly held by Gracell Venture Holdings Limited, representing 75,248,975 ordinary shares, and (ii) 378,511 ADSs that William Wei Cao has the rights to acquire within 60 days of December 31, 2023, representing 1,892,555 ordinary shares. Gracell Venture Holdings Limited is a company incorporated in the British Virgin Islands. Gracell Venture Holdings Limited is wholly owned by Land Blossom Limited, a company incorporated in the British Virgin Islands. Land Blossom Limited, under The Cao Family Trust, or the Trust, established under the law of Republic of Singapore and managed by VISTRA Trust (Singapore) Pte. Limited, or the Trustee, is wholly owned and managed by the Trustee. Dr. William Wei Cao is the Settlor of the Trust and Dr. Cao and his family members are the Trust’s beneficiaries. Under the terms of the Trust, Dr. Cao has the power to direct the Trustee with respect to the retention or disposal of, and the exercise of any voting and other rights attached to the shares held by Gracell Venture Holdings Limited in the Issuer.

     

    (2)Calculation is based on a total of 483,411,767 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    2

     

     

    1 Name of Reporting Person
    Gracell Venture Holdings Limited 
    2

    Check the Appropriate Box if a Member of a Group

    (a)   ¨

    (b)   ¨

    3 SEC Use Only
    4 Citizenship or Place of Organization
    British Virgin Islands  
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    75,248,975 (3)
    6 Shared Voting Power
    0
    7 Sole Dispositive Power
    75,248,975(3)
    8 Shared Dispositive Power
    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    75,248,975 (3)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ¨
    11 Percent of Class Represented by Amount in Row 9
    15.6% (
    4)
    12 Type of Reporting Person
    CO
           

     

    (3)Represents 15,049,795 ADSs, representing 75,248,975 ordinary shares, directly held by Gracell Venture Holdings Limited, a company incorporated in the British Virgin Islands. Gracell Venture Holdings Limited is wholly owned by Land Blossom Limited, a company incorporated in the British Virgin Islands. Land Blossom Limited, under The Cao Family Trust, or the Trust, established under the law of Republic of Singapore and managed by VISTRA Trust (Singapore) Pte. Limited, or the Trustee, is wholly owned and managed by the Trustee. Dr. William Wei Cao is the Settlor of the Trust and Dr. Cao and his family members are the Trust’s beneficiaries. Under the terms of the Trust, Dr. Cao has the power to direct the Trustee with respect to the retention or disposal of, and the exercise of any voting and other rights attached to the shares held by Gracell Venture Holdings Limited in the Issuer.

     

    (4)Calculation is based on a total of 483,411,767 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    3

     

     

    Item 1(a). Name of Issuer:
    Gracell Biotechnologies Inc. (the “Issuer”)
    Item 1(b).

    Address of Issuer’s Principal Executive Offices:
    Building 12, Block B, Phase II

    Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park

    People’s Republic of China

     
    Item 2(a).

    Name of Person Filing:
    (i) William Wei Cao, and

    (ii) Gracell Venture Holdings Limited

    (collectively, the “Reporting Persons”).

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:
    The addresses of the Reporting Persons are:

     

    (i) William Wei Cao:

    Building 12, Block B, Phase II

    Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park

    People’s Republic of China

     

    (ii) Gracell Venture Holdings Limited:

    Sertus Chambers, P.O. Box 905

    Quastisky Building, Road Town, Tortola

    British Virgin Islands

    Item 2(c)

    Citizenship:

    William Wei Cao – People’s Republic of China

    Gracell Venture Holdings Limited – British Virgin Islands

    Item 2(d).

    Title of Class of Securities:

    Ordinary shares, par value US$0.0001 per share

    Item 2(e). CUSIP Number:
    38406L 103. This CUSIP number applies to the American depositary shares, each representing five ordinary shares of the Issuer.
     
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the persons filing is a:
      Not applicable

    Item 4. Ownership:

     

    Reporting Person  Amount
    beneficially
    owned:
      

    Percent
    of class(1):

       Percent of
    aggregate
    voting
    power:
       Sole power to
    vote 
    or direct
    the vote:
       Shared 
    power
    to vote or 
    to direct 
    the vote:
       Sole power 
    to
    dispose or to
    direct the
    disposition 
    of:
       Shared 
    power
    to dispose or
    to direct the
    disposition of:
     
    William Wei Cao   77,141,530    15.9%   15.9%   77,141,530    0    77,141,530    0 
    Gracell Venture Holdings Limited   75,248,975    15.6%   15.6%   75,248,975    0    75,248,975    0 

     

     

    (1)The percentage of class of securities beneficially owned by each Reporting Person is based on a total of 483,411,767 ordinary shares of the Issuer outstanding as of December 31, 2023.

     

    4

     

     

    Item 5. Ownership of Five Percent or Less of a Class:
      Not applicable
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Controlling Person:
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group:
      See Item 2(a) in lieu of an exhibit.
     
    Item 9. Notice of Dissolution of Group:
      Not applicable
       
    Item 10. Certifications:
      Not applicable

     

    5

     

     

    LIST OF EXHIBIT

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

    William Wei Cao 

       
       
      /s/ William Wei Cao
       
       
     

    Gracell Venture Holdings Limited

       
       
      By: /s/ William Wei Cao
      Name: William Wei Cao
      Title: Director

     

     

    Get the next $GRCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRCL

    DatePrice TargetRatingAnalyst
    11/27/2023Outperform
    Evercore ISI
    10/19/2023$11.00Buy
    Stifel
    3/27/2023$7.00Overweight
    Wells Fargo
    12/8/2022$6.00Buy
    H.C. Wainwright
    9/22/2022$12.00Buy
    Citigroup
    8/18/2022Overweight
    Wells Fargo
    6/1/2022$20.00Overweight
    Cantor Fitzgerald
    4/4/2022$18.00Buy
    BTIG Research
    More analyst ratings

    $GRCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

      Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO). In this role, Dr. Li will oversee Gracell's clinical development activities, including the advancement of its pipeline of autologous and allogeneic product candidates across the Company's multiple proprie

      8/1/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

      SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including structuring, negotiating and executing of strategic alliances and collaborations.

      7/19/22 8:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Gracell Biotechnologies

      Evercore ISI initiated coverage of Gracell Biotechnologies with a rating of Outperform

      11/27/23 9:23:35 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Gracell Biotechnologies with a new price target

      Stifel initiated coverage of Gracell Biotechnologies with a rating of Buy and set a new price target of $11.00

      10/19/23 7:15:42 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Gracell Biotechnologies with a new price target

      Wells Fargo resumed coverage of Gracell Biotechnologies with a rating of Overweight and set a new price target of $7.00

      3/27/23 8:58:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gracell Biotechnologies Acquisition Completed

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ("Parent"), and Grey Wolf Merger Su

      2/22/24 8:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by

      2/20/24 7:45:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM). "We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR ca

      1/29/24 7:00:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Financials

    Live finance-specific insights

    See more
    • Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023Presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM); updated data to be reported as an oral presentation at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition (ASH 2023)On track to submit IND filings for planned Phase 1 clinical tr

      11/13/23 7:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

      SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time. Conference call and webcast details:Monday, Nov

      10/30/23 8:30:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update

      Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLEClosed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash run

      8/14/23 7:15:00 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Gracell Biotechnologies Inc.

      15-12G - Gracell Biotechnologies Inc. (0001826492) (Filer)

      3/4/24 12:22:13 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:25 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Gracell Biotechnologies Inc.

      EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)

      2/28/24 12:15:31 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 5:01:37 PM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)

      SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:20:07 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Gracell Biotechnologies Inc.

      SC 13G - Gracell Biotechnologies Inc. (0001826492) (Subject)

      2/14/24 8:00:10 AM ET
      $GRCL
      Biotechnology: Pharmaceutical Preparations
      Health Care